Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Open Access
- 1 February 2008
- journal article
- Published by Elsevier BV in Journal of Lipid Research
- Vol. 49 (2), 394-398
- https://doi.org/10.1194/jlr.m700437-jlr200
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic miceJournal of Lipid Research, 2007
- Molecular biology of PCSK9: its role in LDL metabolismTrends in Biochemical Sciences, 2007
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJCI Insight, 2006
- PCSK9: a promising therapeutic target for dyslipidemias?Trends in Endocrinology & Metabolism, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- The proprotein convertases and their implication in sterol and/or lipid metabolismBiological Chemistry, 2006
- Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartmentProceedings of the National Academy of Sciences of the United States of America, 2005
- NARC-1/PCSK9 and Its Natural MutantsPublished by Elsevier BV ,2004
- Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse LiverPublished by Elsevier BV ,2004
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences of the United States of America, 2004